Traceability in laboratory medicine: a global driver for accurate results for patient care

被引:17
作者
Beastall, Graham H. [1 ]
Brouwer, Nannette [2 ]
Quiroga, Silvia [3 ]
Myers, Gary L. [4 ]
机构
[1] Univ Glasgow, Glasgow G66 1RW, Lanark, Scotland
[2] Waterland Hosp, Diagnost IQ BV, Purmerend, Netherlands
[3] CEMIC Saavedra Univ Hosp, Progba, Buenos Aires, DF, Argentina
[4] Myers Consulting, Smyrna, GA USA
关键词
action plan; commutability; standardization; traceability; LIPID STANDARDIZATION; HARMONIZATION; DISEASE; BLOOD;
D O I
10.1515/cclm-2017-0060
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Laboratory medicine results influence a high percentage of all clinical decisions. Globalization requires that laboratory medicine results should be transferable between methods in the interests of patient safety. International collaboration is necessary to deliver this requirement. That collaboration should be based on traceability in laboratory medicine and the adoption of higher order international commutable reference materials and measurement procedures. Application of the metrological traceability chain facilitates a universal approach. The measurement of serum cholesterol and blood HbA 1c serve as examples of the process of method standardization where an impact on clinical outcomes is demonstrable. The measurement of plasma parathyroid hormone and blood HbA2 serve as examples where the current between-method variability is compromising patient management and method standardization and/ or harmonization is required. Challenges to the widespread adoption of traceability in laboratory medicine include the availability of reference materials and -methods, -geographical differences, the use of variable units, complex analytes and limited global coordination. The global collaboration requires the involvement of several different stakeholder groups ranging from international experts to laboratory medicine specialists in routine clinical laboratories. A coordinated action plan is presented with actions attributable to each of these stakeholder groups.
引用
收藏
页码:1100 / 1108
页数:9
相关论文
共 28 条
[1]   Current parathyroid hormone immunoassays do not adequately meet the needs of patients with chronic kidney disease [J].
Almond, Alison ;
Ellis, Andrew R. ;
Walker, Simon W. .
ANNALS OF CLINICAL BIOCHEMISTRY, 2012, 49 :63-67
[2]  
[Anonymous], 2011, Use of Glycated Haemoglobin (HbA1c) in the Diagnosis of Diabetes Mellitus: Abbreviated Report of a WHO Consultation
[3]  
[Anonymous], DIABETOLOGIA, DOI DOI 10.1007/S00125-007-0789-7
[4]  
[Anonymous], 2009, 151942009 ISO
[5]  
[Anonymous], 2016, CLIN CHEM LAB MED, V54, P1303
[6]  
[Anonymous], 2003, 175112003 ISO
[7]   Adding value to laboratory medicine: a professional responsibility [J].
Beastall, Graham H. .
CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2013, 51 (01) :221-227
[8]  
Daniel Y, 2012, SICKLE CELL THALASSA
[9]   Explaining the decrease in US deaths from coronary disease, 1980-2000 [J].
Ford, Earl S. ;
Ajani, Umed A. ;
Croft, Janet B. ;
Critchley, Julia A. ;
Labarthe, Darwin R. ;
Kottke, Thomas E. ;
Giles, Wayne H. ;
Capewell, Simon .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (23) :2388-2398
[10]   Editorial: Measurement of HbA2 [J].
Giordano, Piero C. .
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2012, 34 (04) :335-335